Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients.
Yeh CN, Chang YC, Su Y, Shin-Shian Hsu D, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Lu ML, Liu CY, Mu-Hsin Chang P, Chen MH, Huang CF, Hsiao M, Chen MH.
Yeh CN, et al. Among authors: huang cf.
Oncotarget. 2017 Dec 8;8(69):113444-113459. doi: 10.18632/oncotarget.23049. eCollection 2017 Dec 26.
Oncotarget. 2017.
PMID: 29371921
Free PMC article.